IDEXX Advances Cancer Detection and Sustainability in 2025 Responsibility Report — IDEXX Laboratories, Inc.

Event summary

IDEXX launched the IDEXX Cancer Dx™ Panel for canine lymphoma detection and new FNA cytology capabilities for mast cell tumors.
The company helped enable access to care for over 45,000 animals in underserved communities in 2025.
IDEXX logged 121,400 hours of learning and development, including 46,700 hours of STEM and AI learning.
The company signed its first virtual power purchase agreement (VPPA) in Europe, bringing the total to three VPPAs expected to cover 100% of North American and European electricity consumption.

The big picture

IDEXX's 2025 Corporate Responsibility Report underscores the company's strategic focus on integrating innovation with sustainability. The advancements in cancer detection and diagnostic imaging align with broader industry trends toward precision medicine, while its sustainability initiatives reflect growing regulatory and investor pressures for environmental accountability. With a global footprint and significant investments in R&D, IDEXX is positioning itself as a leader in both veterinary healthcare and corporate responsibility.

What we're watching

Innovation Pace: How IDEXX will sustain its innovation pipeline in veterinary diagnostics, particularly in cancer detection and imaging technology.
Sustainability Goals: Whether IDEXX can meet its 2030 GHG emissions reduction target with current initiatives.
Market Expansion: The pace at which IDEXX extends its reach into underserved veterinary markets globally.